

Dear AXSANA study sites,

More than two and a half years after the initiation of the AXSANA study, we can still report a high recruitment rate. For this we would like to thank all participating study centers sincerely. If recruitment continues to be so successful, we will reach the recruitment target already this year and thus ahead of schedule. Therefore, we ask all of you to continue to enroll your patients in the study. With this newsletter we would like to inform you about the results of the recently finished first data completing campaign, the current recruitment status and scientific activities.

In the name of the International Steering Committee and the Organizing Committee,

Prof. T. Kühn PD M. Banys-Paluchowski Ass. Prof. J. de Boniface Prof. E. Stickeler Dr. O. Gentilini PD S. Hartmann

Important:

- Please consistently perform and document annual follow-ups beginning 1 year after surgery in all ycN0-patients.

Data-completing campaign

- Thanks to your dedicated help, we were able to successfully complete our first data-completing campaign on January 31, 2023.
- One result of the campaign is that records are available for 92% of patients up to and including CRF 5 (planned adjuvant treatment). For 81% of the patients, these data sets are already complete, i.e. no more queries need to be answered.
- However, data for the first follow-up one year after surgery are currently missing for 21% of the study participants.
- **Therefore, we ask you not only to consistently continue to complete the data for all patients up to and including CRF 5, but also to be strictly sure to perform and document the annual follow-up (CRF6a/b, CRF7a-d, years 1-5 after surgery) for all ycN0-patients.**
- A second data-completing campaign is planned for the upcoming autumn after the recruitment target of 4500 study participants has been reached. We ask for your support again, because for the evaluation of the AXSANA study objectives only data sets of completely documented patients (including follow-up) can be used.

Quality of life (QoL)


- **A high response rate of the QoL questionnaires is crucial for the reliability of QoL data evaluation.**
- About 400 baseline questionnaires, confirmed completed in CRF 2 are still missing. If you have completed paper questionnaires at your site, please send them immediately to qol-axsana@eubreast.com. Do not transfer the data from the paper forms to the online forms independently.
- Please use postal reminder if questionnaires are not answered within one month of sending the one-year post surgery follow-up questionnaire to the participant.
Contact for QoL questionnaires: matilda.appelgren@ki.se

Scientific Activities

- You can find all previous full-text publications and congress papers of the AXSANA Study Group at <https://www.eubreast.com/?Trials/AXSANA#Publications>.
- The current status of the AXSANA study has been presented recently in the Ongoing Trials session at the SABCS 2022.
- This year we are also planning presentations at national and international congresses and publications of initial interim analyses.

International Recruitment

- By March 1, 2023, 3.647 patients had been enrolled in the study.
- Patients from 24 countries have been recruited.
- Belgium, Great Britain, Hongkong and Mexico are the newest members of the AXSANA study group and will start recruiting soon.
- As more than 100 patients per month are currently enrolled in the study, the recruitment target is achievable before 2025 (as initially planned).
- **Therefore, please continue to maintain the high recruitment rate!**



country	no. of enrolled patients
Albania	62
Austria	40
Azerbaijan	66
Bulgaria	1
Czech Republic	5
Finland	49
Germany	2037
Greece	97
Hungary	2
India	26
Israel	18
Italy	175
N.N.	25
Norway	44
Peru	43
Poland	131
Portugal	63
Romania	53
Slowenia	13
Spain	156
Sweden	146
Switzerland	21
Thailand	14
Turkey	360

country	national coordinator	top-recruiter - PI	pat.
Albania	Prof. Nina Helidon	Oncological Hospital Tirana – Prof. Helidon	62
Austria	Univ.-Prof. Florentia Peintinger	LKH University of Graz – Prof. Peintinger	23
Azerbaijan	Ass. Prof. Hagigat Valiyeva	Medical University Baku – Prof. Valiyeva	66
Bulgaria	Dr. Tsvetomir Ivanov, Ph.D.	Heart and Brain Hospital Pleven – Dr. Tsvetomir	1
Czech Republic	Dr. Lukas Dostalek	Charles University, General University Hospital, Prague – Dr. Dostalek	5
Finland	Dr. Laura Niinikoski	Helsinki University Hospital – Dr. Niinikoski	49
Germany	PD Maggie Banys-Paluchowski	University of Tuebingen – Prof. Hahn	88
Greece	Prof. Michalis Kontos	Anticancer Hospital Theageneio Thessaloniki – Dr. Iosifidou	27
Hungary	Dr. Zoltan Matrai	National Institut of Oncology, Budapest	2
India	Dr. Geeta Kadayaprath	MAX Hospital, Vaishali, New Delhi – Dr. Arun Kumar Goel	16
Isreal	Dr. Dov Zippel	Sheba Medical Centre Tel Aviv – Dr. Zippel	16
Italy	Dr. Oreste Gentilini	Breast Unit S. Anna Hospital Torino – Italy – Dr. Porpiglia	48
Norway	Dr. Ellen Schlichting	Oslo University Hospital – Dr. Schlichting	29
Peru	Dr. Lia Rebaza Vasquez	Oncosalud-AUNA Clinic Lima – Dr. Vasquez	43
Poland	Prof. Dawid Murawa	Greater Poland Cancer Centre Poznan – Dr. Adamczyk	53
Portugal	Dr. David Pinto	Champalimaud Clinical Center Lisboa – Dr. Pinto	20
Romania	Dr. Eduard-Alexandru Bonci	„Prof. Dr. Ion Chiricuta“ Institute of Oncology, Cluj Napoca – Dr. Bonci	34
Slowenia	Dr. Andraz Perhavec	Institute of Oncology Ljubljana – Dr. Perhavec	13
Spain	Dr. Isabel Rubio	Unidad de Patologia Mamaria, Hospital San Cecilio, Granada – Dr. Sanchez Barron	51
Sweden	Ass. Prof. Jana de Boniface	St. Görans Sjukhus – Dr. Zetterlund	45
Switzerland	Dr. Maria Luisa Gasparri	University of the Italian Switzerland, Lugano – Dr. Gasparri	9
Thailand	Dr. Sarun Thongvitokomarn	Queen Sirikit Centre for Breast Cancer Bangkok – Dr. Thongvitokomarn	14
Turkey	Prof. Guldeniz Karadeniz Cakmak	Zonguldak Bulent Ecevit University, The School of Medicine – Prof. Karadeniz Cakmak	94

IMPRESSUM

EUBREAST Study Group

Chairs and Co-Chairs:

Prof. T. Kühn, Prof. E. Stickeler,
Prof. J. de Boniface, Dr. O. Gentilini

Organizing Committee:

Prof. T. Kühn: t.kuehn@filderklinik.de

PD Dr. M. Banys-Paluchowski: m.banys@outlook.com

PD Dr. S. Hartmann: steffi.hartmann@kliniksued-rostock.de

International study coordination:

Ass. Prof. B. Aktas and Dr. M. Mangold

axsana@eubreast.com

Tel. +49 711 3103 3063

**In case of questions do not hesitate to
contact your National Steering Committee!**

